| BCR-ABL1 Major (p210) | Relative quantitation of fusion transcripts resulting from t(9;22)(q34;q11.2) translocation with major (p210) BCR-ABL1 breakpoint. Note: This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the minor (p190) and the micro (p230) breakpoints. |
| BCR-ABL1 Minor (p190) | Relative quantitation of fusion transcripts resulting from t(9;22)(q34;q11.2) translocation with minor (p190) BCR-ABL1 breakpoint. Note: This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the major (p210) and the micro (p230) breakpoints. |
| BCR-ABL1 Major (p210) | The QuantideX® qPCR BCR-ABL Major Kit is an in vitro nucleic acid amplification test for the relative quantitation of BCR-ABL1 major and endogenous ABL1 transcripts in total RNA. It is a multiplex reverse transcription-quantitative RT-PCR hydrolysis probe technology performed on the Applied Biosystems 7500 Fast Dx Instrument. |
| BCR-ABL1 Minor (p190) | The QuantideX® qPCR BCR-ABL1 Minor Kit is an in vitro nucleic acid amplification test for the relative quantitation of BCR-ABL1 minor and endogenous ABL1 transcripts in total RNA. It is a multiplex reverse transcription-quantitative RT-PCR hydrolysis probe technology performed on the Applied Biosystems 7500 Fast Dx Instrument. |
| BCR-ABL1 Major (p210) | This test can be used to monitor response to therapy for disorders including chronic myeloid leukemia (CML) and B-lymphoblastic leukemia (B-ALL) in which a t(9:22)(q34q11.2) reciprocal translocation with a major (p210) BCR-ABL1 breakpoint can be found. |
| BCR-ABL1 Minor (p190) | This test can be used to monitor response to therapy for disorders including chronic myeloid leukemia (CML) and B-lymphoblastic leukemia (B-ALL) in which a t(9:22)(q34q11.2) reciprocal translocation with a minor (p190) BCR-ABL1 breakpoint can be found. |
| BCR-ABL1 Major (p210) | This test is only designed to detect e13a2 and e14a2 fusion transcripts resulting from a major (p210) BCR-ABL1 breakpoint. This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the minor (p190) and the micro (p230) breakpoints. |
| BCR-ABL1 Minor (p190) | This test is only designed to detect e13a2 and e14a2 fusion transcripts resulting from a minor (p190) BCR-ABL1 breakpoint. This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the major (p210) and the micro (p230) breakpoints. |
| BCR-ABL1 Major (p210) | No major (p210) BCR-ABL1 fusion transcript detected. |
| BCR-ABL1 Minor (p190) | No major (p190) BCR-ABL1 fusion transcript detected. |
| BCR-ABL1 Major (p210) | If detected, a ratio of the major (p210) BCR-ABL1 fusion transcript level to the endogenous ABL1 transcript level is reported on an international scale (IS) along with a molecular reduction (MR) value. |
| BCR-ABL1 Minor (p190) | If detected, a ratio of the minor (p190) BCR-ABL1 fusion transcript level to the endogenous ABL1 transcript level is reported on %ratio. |
| Test Information |
| BCR-ABL1 Major (p210) | Relative quantitation of fusion transcripts resulting from t(9;22)(q34;q11.2) translocation with major (p210) BCR-ABL1 breakpoint. Note: This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the minor (p190) and the micro (p230) breakpoints. |
| BCR-ABL1 Minor (p190) | Relative quantitation of fusion transcripts resulting from t(9;22)(q34;q11.2) translocation with minor (p190) BCR-ABL1 breakpoint. Note: This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the major (p210) and the micro (p230) breakpoints. |
| BCR-ABL1 Major (p210) | The QuantideX® qPCR BCR-ABL Major Kit is an in vitro nucleic acid amplification test for the relative quantitation of BCR-ABL1 major and endogenous ABL1 transcripts in total RNA. It is a multiplex reverse transcription-quantitative RT-PCR hydrolysis probe technology performed on the Applied Biosystems 7500 Fast Dx Instrument. |
| BCR-ABL1 Minor (p190) | The QuantideX® qPCR BCR-ABL1 Minor Kit is an in vitro nucleic acid amplification test for the relative quantitation of BCR-ABL1 minor and endogenous ABL1 transcripts in total RNA. It is a multiplex reverse transcription-quantitative RT-PCR hydrolysis probe technology performed on the Applied Biosystems 7500 Fast Dx Instrument. |
| BCR-ABL1 Major (p210) | This test can be used to monitor response to therapy for disorders including chronic myeloid leukemia (CML) and B-lymphoblastic leukemia (B-ALL) in which a t(9:22)(q34q11.2) reciprocal translocation with a major (p210) BCR-ABL1 breakpoint can be found. |
| BCR-ABL1 Minor (p190) | This test can be used to monitor response to therapy for disorders including chronic myeloid leukemia (CML) and B-lymphoblastic leukemia (B-ALL) in which a t(9:22)(q34q11.2) reciprocal translocation with a minor (p190) BCR-ABL1 breakpoint can be found. |
| BCR-ABL1 Major (p210) | This test is only designed to detect e13a2 and e14a2 fusion transcripts resulting from a major (p210) BCR-ABL1 breakpoint. This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the minor (p190) and the micro (p230) breakpoints. |
| BCR-ABL1 Minor (p190) | This test is only designed to detect e13a2 and e14a2 fusion transcripts resulting from a minor (p190) BCR-ABL1 breakpoint. This test is not designed to detect fusion transcripts resulting from other BCR-ABL1 breakpoints such as the major (p210) and the micro (p230) breakpoints. |
| Specimen Collection and Handling |
| Result Interpretation |
| BCR-ABL1 Major (p210) | No major (p210) BCR-ABL1 fusion transcript detected. |
| BCR-ABL1 Minor (p190) | No major (p190) BCR-ABL1 fusion transcript detected. |
| BCR-ABL1 Major (p210) | If detected, a ratio of the major (p210) BCR-ABL1 fusion transcript level to the endogenous ABL1 transcript level is reported on an international scale (IS) along with a molecular reduction (MR) value. |
| BCR-ABL1 Minor (p190) | If detected, a ratio of the minor (p190) BCR-ABL1 fusion transcript level to the endogenous ABL1 transcript level is reported on %ratio. |
